Anzeige
Mehr »
Samstag, 25.10.2025 - Börsentäglich über 12.000 News
Das nächste Lila Sciences? Telescope Innovations ist das 30-Millionen-Dollar-Tor zu KI-gesteuerter Chemie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DMJQ | ISIN: CA53946V2066 | Ticker-Symbol: 6YX0
Frankfurt
24.10.25 | 08:04
0,020 Euro
-6,98 % -0,002
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
LOBE SCIENCES LTD Chart 1 Jahr
5-Tage-Chart
LOBE SCIENCES LTD 5-Tage-Chart

Aktuelle News zur LOBE SCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrLobe Sciences Ltd.: Lobe Sciences Completes Debt Settlement to Improve Balance Sheet197VANCOUVER, BC / ACCESS Newswire / October 23, 2025 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), operates as a pharmaceutical platform that develops novel therapies...
► Artikel lesen
09.10.Lobe Sciences Ltd (2): Lobe Sciences arranges $137,130 (U.S.) debt settlement1
09.10.Lobe Sciences Ltd.: Lobe Sciences Improves Balance Sheet140VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / October 9, 2025 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), operates as a pharmaceutical platform that develops...
► Artikel lesen
16.09.ArcStone US Corp.: Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto511Vancouver, British Columbia--(Newsfile Corp. - September 15, 2025) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (FSE: LOBE.F) ("Lobe Sciences" or the "Company") a clinical stage biopharmaceutical...
► Artikel lesen
10.09.Lobe Sciences Ltd. and Cynaptec Pharmaceuticals, Inc. to Present a New Therapeutic Approach for the Treatment of Chronic Cluster Headaches at Clusterbusters 2025391VANCOUVER, B.C. / ACCESS Newswire / September 9, 2025 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) a clinical stage biopharmaceutical company focused on developing...
► Artikel lesen
09.09.Lobe Sciences Ltd.: Lobe Sciences Announces the Appointment of Marco Mastrodonato to its Board of Directors347VANCOUVER, BC / ACCESS Newswire / September 8, 2025 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) a clinical stage biopharmaceutical company focused on...
► Artikel lesen
LOBE SCIENCES Aktie jetzt für 0€ handeln
15.08.Lobe Sciences Ltd.: Lobe Sciences Announces the Closing of the Previously Announced Private Placement394NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / August 14, 2025 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company")...
► Artikel lesen
29.07.Lobe Sciences Ltd (2): Lobe Sciences hires ArcStone for advisory services1
29.07.Lobe Sciences Ltd (2): Lobe Sciences arranges private placement2
29.07.Lobe Sciences Ltd.: Lobe Sciences Announces $341,425 CAD Private Placement for General Corporate Purposes441NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / July 29, 2025 / Lobe Sciences Ltd. ("Lobe Sciences"...
► Artikel lesen
29.07.Lobe Sciences Ltd. Engages ArcStone Securities for Strategic Capital Markets Advisory419VANCOUVER, BC / ACCESS Newswire / July 29, 2025 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a biopharmaceutical company focused on developing therapeutics for rare and underserved diseases...
► Artikel lesen
17.07.Lobe Sciences Ltd (2): Lobe Sciences issues 546,206 shares for debt of $11,5962
17.07.Lobe Sciences announces debt settlement-
17.07.Lobe Sciences Ltd. Announces Debt Settlement382VANCOUVER, BC / ACCESS Newswire / July 16, 2025 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a biopharmaceutical company committed to developing innovative treatments for underserved diseases...
► Artikel lesen
08.07.Lobe Sciences Ltd (2): Lobe Sciences receives European unitary patent1
08.07.Lobe Sciences Ltd.: Lobe Sciences Announces Validation of European Unitary Patent for DHA-Based Composition for Sickle Cell Disease667European Unitary Patent EP4117446 Validated - Lobe Sciences secures patent protection in 17 EU member states for its DHA and egg yolk-based composition designed to manage Sickle Cell Disease.Covers...
► Artikel lesen
18.06.Lobe Sciences Ltd.: Lobe Sciences Moves Forward with Development of Conjugated Psilocin Following April 14 Agreement to Spin Out Compound to Cynaptec Pharmaceuticals312New subsidiary, Cynaptec Pharmaceuticals, established to hold global rights to Conjugated Psilocin$6 million investment in Cynaptec Pharmaceuticals secured to advance research and early-stage clinical...
► Artikel lesen
03.06.Lobe Sciences Ltd (2): Lobe Sciences appoints Yao as CFO, EVP3
03.06.Lobe Sciences Ltd.: Lobe Sciences Appoints Mr. Yong Yao as Chief Financial Officer to Support Strategic Growth343Lobe Sciences Ltd. has appointed Mr. Yong Yao as Chief Financial Officer and Executive Vice President, effective June 1, 2025, to lead the company's financial strategy during its next phase of growth.Mr....
► Artikel lesen
14.04.Lobe Sciences Ltd. Announces Private Placement to Support Drug Development of Novel Conjugated Psilocin226Private Placement of US$6 Million to fund additional pre-clinical research, Phase 1 and Phase 2a clinical studiesUS$20 Million additional option included in Private Placement to fund the Phase 3 clinical...
► Artikel lesen
Weiter >>
21 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1